Join to view full profile
1111 Highland AveWIMR1 Rm 4033Madison, WI 53705
Phone+1 608-265-0106
Fax+1 608-234-4383
Dr. Liu is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Hongtao Liu is an oncologist in Madison, WI and is affiliated with University of Wisconsin-Madison. He received his medical degree from Beijing Medical University and has been in practice 24 years. He specializes in hematologic oncology and is experienced in amyloidosis, hematologic oncology, myelodysplasia, myelofibrosis, and hematopoietic stem cell transplantation.
Education & Training
University of ChicagoFellowship, Hematology and Medical Oncology, 2008 - 2011
Texas Tech University (Amarillo)Residency, Internal Medicine, 2005 - 2008
Beijing Medical UniversityClass of 1993
Certifications & Licensure
WI State Medical License 2023 - 2027
IL State Medical License 2007 - 2026
American Board of Internal Medicine Hematology- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2014, 2016-2017
- CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2014, 2016-2017
- CMS Meaningful Use Stage 2 Certification EpicCare Inpatient 2014 Certified EHR Suite, Epic Systems Corporation, 2014, 2016-2017
Clinical Trials
- Donor T Cells After Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies Start of enrollment: 2013 Apr 04
- Vaccine Therapy and Basiliximab in Treating Patients With Acute Myeloid Leukemia in Complete Remission Start of enrollment: 2011 Dec 05
- Selinexor (KPT-330) in Older Patients With Relapsed AML
Publications & Presentations
PubMed
- Impact of Area Deprivation Index in patients with newly diagnosed acute myeloid leukemia treated with a venetoclax-based regimen: a single-center retrospective study.Bradley Uyemura, Fauzia Hollnagel, Aric Hall, Mathew Brunner, Zhubin Gahvari
Leukemia & Lymphoma. 2026-08-16 - Infections Within 100 Days of Idecabtagene Vicleucel and Impact on Survival for Relapsed/Refractory Multiple Myeloma: A CIBMTR Analysis.Kitsada Wudhikarn, Lohith Gowda, Qiran Ye, Temitope Oloyede, Michael Martens
Transplantation and Cellular Therapy. 2026-06-27 - 1 citationsProlonged Cytopenia After Idecabtagene Vicleucel for Multiple Myeloma is Associated with Poor Overall Survival.Gurbakhash Kaur, Jennifer Logue, Ruta Brazauskas, Temitope Oloyede, Muhammad Bilal Abid
Transplantation and Cellular Therapy. 2026-06-16
Abstracts/Posters
- Feasibility and Outcomes of T-Cell Depleted Hematopoietic Stem Cell Transplantation in Patients with Relapsed or Refractory AML and High Risk MDSHongtao Liu, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Outcomes of IDH-Mutated Advanced Phase Ph-Negative Myeloproliferative Neoplasms Treated with IDH InhibitorsHongtao Liu, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Press Mentions
The Immunotherapy RevolutionMay 3rd, 2017
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: